The AAPS Journal最新文献_第2页

Preliminary Investigation of a Rapid and Feasible Therapeutic Drug Monitoring Method for the Real-Time Estimation of Blood Pazopanib Concentrations 实时估算帕唑帕尼血药浓度的快速可行治疗药物监测方法初探

The AAPS Journal Pub Date : 2024-04-15 DOI: 10.1208/s12248-024-00918-6

Masaru Kato, Shinichi Maruyama, Noriko Watanabe, Risa Yamada, Yuki Suzaki, Masaru Ishida, Hiroshi Kanno

{"title":"Preliminary Investigation of a Rapid and Feasible Therapeutic Drug Monitoring Method for the Real-Time Estimation of Blood Pazopanib Concentrations","authors":"Masaru Kato, Shinichi Maruyama, Noriko Watanabe, Risa Yamada, Yuki Suzaki, Masaru Ishida, Hiroshi Kanno","doi":"10.1208/s12248-024-00918-6","DOIUrl":"https://doi.org/10.1208/s12248-024-00918-6","url":null,"abstract":"<p>Pazopanib is a multi-kinase inhibitor used to treat advanced/metastatic renal cell carcinoma and advanced soft tissue tumors; however, side effects such as diarrhea and hypertension have been reported, and dosage adjustment based on drug concentration in the blood is necessary. However, measuring pazopanib concentrations in blood using the existing methods is time-consuming; and current dosage adjustments are made using the results of blood samples taken at the patient's previous hospital visit (approximately a month prior). If the concentration of pazopanib could be measured during the waiting period for a doctor’s examination at the hospital (in approximately 30 min), the dosage could be adjusted according to the patient's condition on that day. Therefore, we aimed to develop a method for rapidly measuring blood pazopanib concentrations (in approximately 25 min) using common analytical devices (a tabletop centrifuge and a spectrometer). This method allowed for pazopanib quantification in the therapeutic concentration range (25–50 μg/mL). Additionally, eight popular concomitant medications taken simultaneously with pazopanib did not interfere with the measurements. We used the developed method to measure blood concentration in two patients and obtained similar results to those measured using the previously reported HPLC method. By integrating it with the point of care and sample collection by finger pick, this method can be used for measurements in pharmacies and patients' homes. This method can maximize the therapeutic effects of pazopanib by dose adjustment to control adverse events.</p>","PeriodicalId":501692,"journal":{"name":"The AAPS Journal","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140587835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ginsenoside Rg1 Alleviates Sepsis-Induced Acute Lung Injury by Reducing FBXO3 Stability in an m6A-Dependent Manner to Activate PGC-1α/Nrf2 Signaling Pathway 人参皂苷 Rg1 依赖 m6A 降低 FBXO3 稳定性以激活 PGC-1α/Nrf2 信号通路，从而缓解败血症诱导的急性肺损伤

The AAPS Journal Pub Date : 2024-04-15 DOI: 10.1208/s12248-024-00919-5

Rong Liu, Qiang Wang, Yao Li, Ruixue Wan, Ping Yang, Dexing Yang, Jiefu Tang, Jiafei Lu

{"title":"Ginsenoside Rg1 Alleviates Sepsis-Induced Acute Lung Injury by Reducing FBXO3 Stability in an m6A-Dependent Manner to Activate PGC-1α/Nrf2 Signaling Pathway","authors":"Rong Liu, Qiang Wang, Yao Li, Ruixue Wan, Ping Yang, Dexing Yang, Jiefu Tang, Jiafei Lu","doi":"10.1208/s12248-024-00919-5","DOIUrl":"https://doi.org/10.1208/s12248-024-00919-5","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>Sepsis-induced acute lung injury (ALI) is one of the serious life-threatening complications of sepsis and is pathologically associated with mitochondrial dysfunction. Ginsenoside Rg1 has good therapeutic effects on ALI. Herein, the pharmacological effects of Rg1 in sepsis-induced ALI were investigated.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p><i>S</i>epsis-induced ALI models were established by CLP operation and LPS treatment. HE staining was adopted to analyze lung pathological changes. The expression and secretion of cytokines were measured by RT-qPCR and ELISA. Cell viability and apoptosis were assessed by MTT assay, flow cytometry and TUNEL staining. ROS level and mitochondrial membrane potential (MMP) were analyzed using DHE probe and JC-1 staining, respectively. FBXO3 m<sup>6</sup>A level was assessed using MeRIP assay. The interactions between FBXO3, YTHDF1, and PGC-1α were analyzed by Co-IP or RIP.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Rg1 administration ameliorated LPS-induced epithelial cell inflammation, apoptosis, and mitochondrial dysfunction in a dose-dependent manner. Mechanically, Rg1 reduced PGC-1α ubiquitination modification level by inhibiting FBXO3 expression m<sup>6</sup>A-YTHDF1 dependently. As expected, Rg1’s mitigative effect on LPS-induced inflammation, apoptosis and mitochondrial dysfunction in lung epithelial cells was abolished by FBXO3 overexpression. Moreover, FBXO3 upregulation eliminated the restoring effect of Rg1 on CLP-induced lung injury in rats.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>Rg1 activated PGC-1α/Nrf2 signaling pathway by reducing FBXO3 stability in an m<sup>6</sup>A-YTHDF1-dependent manner to improve mitochondrial function in lung epithelial cells during sepsis-induced ALI progression.</p><h3 data-test=\"abstract-sub-heading\">Graphical Abstract</h3>\u0000","PeriodicalId":501692,"journal":{"name":"The AAPS Journal","volume":"44 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140587944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bile Acid–Targeted Hyaluronic Acid Nanoparticles for Enhanced Oral Absorption of Deferoxamine 胆汁酸靶向透明质酸纳米粒子用于增强对去铁胺的口服吸收

The AAPS Journal Pub Date : 2024-04-12 DOI: 10.1208/s12248-024-00911-z

Elizabeth Oladoyin Agboluaje, Shuolin Cui, Neil J. Grimsey, May P. Xiong

{"title":"Bile Acid–Targeted Hyaluronic Acid Nanoparticles for Enhanced Oral Absorption of Deferoxamine","authors":"Elizabeth Oladoyin Agboluaje, Shuolin Cui, Neil J. Grimsey, May P. Xiong","doi":"10.1208/s12248-024-00911-z","DOIUrl":"https://doi.org/10.1208/s12248-024-00911-z","url":null,"abstract":"<p>Patients with β-thalassemia and sickle cell disease often rely on blood transfusions which can lead to hemochromatosis and chronic oxidative stress in cells and tissues. Deferoxamine (DFO) is clinically approved to treat hemochromatosis but is suboptimal to patients due to its poor pharmacokinetics which requires long-term infusion regimens. Although the oral route is preferable, DFO has limited oral bioavailability. Studies have shown that hyaluronic acid (HA) and bile acid (BA) can enhance the oral absorption of poorly absorbed drugs. To improve upon the oral delivery of DFO, we report on the synthesis and characterization of HA (MW 15 kD) conjugated to two types of BA, deoxycholic acid (DOCA) and taurocholic acid (TCA), and DFO. The resulting seven polymeric conjugates all formed self-assembled nanoparticles. The degree of BA and DFO conjugation to the HA polymer was confirmed at each step through nuclear magnetic resonance, Fourier transform infrared spectroscopy, and UV–Vis spectroscopy. The best formulations for further <i>in vitro</i> testing were determined based on physicochemical characterizations and included HA-DFO, TCA<sub>9</sub>-HA-DFO, and DOCA<sub>9</sub>-HA-DFO. Results from <i>in vitro</i> assays revealed that TCA<sub>9</sub>-HA-DFO enhanced the permeation of DFO the most and was also less cytotoxic to cells compared to the free drug DFO. In addition, ferritin reduction studies indicated that the conjugation of DFO to TCA<sub>9</sub>-HA did not compromise its chelation efficiency at equivalent free DFO concentrations. This research provides supportive data for the idea that TCA conjugated to HA may enhance the oral absorption of DFO, improve its cytocompatibility, and maintain its iron chelation efficiency.</p><h3 data-test=\"abstract-sub-heading\">Graphical Abstract</h3>\u0000","PeriodicalId":501692,"journal":{"name":"The AAPS Journal","volume":"122 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140602395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Leveraging Modeling and Simulation to Enhance the Efficiency of Bioequivalence Approaches for Generic Drugs: Highlights from the 2023 Generic Drug Science and Research Initiatives Public Workshop 利用建模和模拟提高仿制药生物等效性方法的效率：2023 年仿制药科学与研究计划公开研讨会要点

The AAPS Journal Pub Date : 2024-04-08 DOI: 10.1208/s12248-024-00916-8

Arindom Pal, Fang Wu, Ross Walenga, Eleftheria Tsakalozou, Khondoker Alam, Yuqing Gong, Liang Zhao, Lanyan Fang

{"title":"Leveraging Modeling and Simulation to Enhance the Efficiency of Bioequivalence Approaches for Generic Drugs: Highlights from the 2023 Generic Drug Science and Research Initiatives Public Workshop","authors":"Arindom Pal, Fang Wu, Ross Walenga, Eleftheria Tsakalozou, Khondoker Alam, Yuqing Gong, Liang Zhao, Lanyan Fang","doi":"10.1208/s12248-024-00916-8","DOIUrl":"https://doi.org/10.1208/s12248-024-00916-8","url":null,"abstract":"<p>The 2023 Generic Drug Science and Research Initiative Public Workshop organized by the U.S. Food and Drug Administration (FDA) discussed the research needs to improve and enhance bioequivalence (BE) approaches for generic drug development. FDA takes such research needs and panel discussions into account to develop its Generic Drug User Fee Amendments III (GDUFA III) Science and Research Initiatives specific to generics. During the five workshop sessions, presentations and panel discussions focused on identifying and addressing scientific gaps and research needs related to nitrosamine impurity issues, BE assessment for oral products, innovative BE approaches for long-acting injectable products, alternative BE approaches for orally inhaled products, and advanced BE methods for topical products. Specifically, this report highlights the discussions on how to improve BE assessment for developing generic drug products based on research priorities for leveraging quantitative methods and modeling, as well as artificial intelligence/machine learning (AI/ML).</p><h3 data-test=\"abstract-sub-heading\">Graphical Abstract</h3>\u0000","PeriodicalId":501692,"journal":{"name":"The AAPS Journal","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140587649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mechanistic Modeling of In Vitro Biopharmaceutic Data for a Weak Acid Drug: A Pathway Towards Deriving Fundamental Parameters for Physiologically Based Biopharmaceutic Modeling 弱酸性药物体外生物制药数据的机理建模：为基于生理学的生物制药建模推导基本参数的途径

The AAPS Journal Pub Date : 2024-04-04 DOI: 10.1208/s12248-024-00912-y

Venkata Krishna Kowthavarapu, Nitin Bharat Charbe, Churni Gupta, Tatiana Iakovleva, Cordula Stillhart, Neil John Parrott, Stephan Schmidt, Rodrigo Cristofoletti

{"title":"Mechanistic Modeling of In Vitro Biopharmaceutic Data for a Weak Acid Drug: A Pathway Towards Deriving Fundamental Parameters for Physiologically Based Biopharmaceutic Modeling","authors":"Venkata Krishna Kowthavarapu, Nitin Bharat Charbe, Churni Gupta, Tatiana Iakovleva, Cordula Stillhart, Neil John Parrott, Stephan Schmidt, Rodrigo Cristofoletti","doi":"10.1208/s12248-024-00912-y","DOIUrl":"https://doi.org/10.1208/s12248-024-00912-y","url":null,"abstract":"<p>Mechanistic modeling of <i>in vitro</i> experiments using metabolic enzyme systems enables the extrapolation of metabolic clearance for <i>in vitro-in vivo</i> predictions. This is particularly important for successful clearance predictions using physiologically based pharmacokinetic (PBPK) modeling. The concept of mechanistic modeling can also be extended to biopharmaceutics, where <i>in vitro</i> data is used to predict the <i>in vivo</i> pharmacokinetic profile of the drug. This approach further allows for the identification of parameters that are critical for oral drug absorption <i>in vivo</i>. However, the routine use of this analysis approach has been hindered by the lack of an integrated analysis workflow. The objective of this tutorial is to (1) review processes and parameters contributing to oral drug absorption in increasing levels of complexity, (2) outline a general physiologically based biopharmaceutic modeling workflow for weak acids, and (3) illustrate the outlined concepts via an ibuprofen (i.e., a weak, poorly soluble acid) case example in order to provide practical guidance on how to integrate biopharmaceutic and physiological data to better understand oral drug absorption. In the future, we plan to explore the usefulness of this tutorial/roadmap to inform the development of PBPK models for BCS 2 weak bases, by expanding the stepwise modeling approach to accommodate more intricate scenarios, including the presence of diprotic basic compounds and acidifying agents within the formulation.</p><h3 data-test=\"abstract-sub-heading\">Graphical Abstract</h3>\u0000","PeriodicalId":501692,"journal":{"name":"The AAPS Journal","volume":"2016 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140587666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oral Drug Product Administration via Enteral Feeding Tubes: In Vitro Testing 通过肠内喂养管进行口服药物给药：体外测试

The AAPS Journal Pub Date : 2024-04-04 DOI: 10.1208/s12248-024-00896-9

Selina Wilson, Julianne Farabaugh, Yemin Liu, Zhao Liu, Rachel Meyers, Matthew Santangelo, Karen Thompson

{"title":"Oral Drug Product Administration via Enteral Feeding Tubes: In Vitro Testing","authors":"Selina Wilson, Julianne Farabaugh, Yemin Liu, Zhao Liu, Rachel Meyers, Matthew Santangelo, Karen Thompson","doi":"10.1208/s12248-024-00896-9","DOIUrl":"https://doi.org/10.1208/s12248-024-00896-9","url":null,"abstract":"<p>Medication administration <i>via</i> enteral feeding tubes (EFT) is a necessary practice for patients unable to swallow oral dosage forms due to a medical condition or treatment that affects the ability to swallow or the function of the gastrointestinal tract. Off-label administration of oral drug products <i>via</i> EFT raises concerns for pharmaceutical sponsors, regulators, and healthcare practitioners (HCPs) because of the potential risks this practice introduces to both the patient and the caregiver. These risks can be mitigated by generating data-supported instructions that patients and HCPs can use to ensure safe and accurate administration of oral drug products <i>via</i> EFT. This commentary presents an industry perspective on the testing that should be conducted to enable development of product-specific instructions in the labeling to support or advise against administration of oral drug products <i>via</i> enteral feeding tube. The proposal outlined in this commentary takes a risk-based approach, addressing recommendations from both regulatory agencies as well as considerations for expanding this testing to address needs specific to neonatal and pediatric populations.</p><h3 data-test=\"abstract-sub-heading\">Graphical Abstract</h3>\u0000","PeriodicalId":501692,"journal":{"name":"The AAPS Journal","volume":"50 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140587838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Predicting the Stability of Lyophilized Human Serum Albumin Formulations Containing Sucrose and Trehalose Using Solid-State NMR Spectroscopy: Effect of Storage Temperature on 1H T1 Relaxation Times 利用固态 NMR 光谱预测含有蔗糖和曲哈糖的冻干人血清白蛋白制剂的稳定性：储存温度对 1H T1 松弛时间的影响

The AAPS Journal Pub Date : 2024-04-03 DOI: 10.1208/s12248-024-00900-2

引用次数: 0

PmWebSpec: An Application to Create and Manage CDISC-Compliant Pharmacometric Analysis Dataset Specifications PmWebSpec：创建和管理符合 CDISC 标准的药物计量分析数据集规范的应用程序

The AAPS Journal Pub Date : 2024-04-03 DOI: 10.1208/s12248-024-00910-0

Lu Chen, Erin Dombrowsky, Baylea Boyle, Chengke Tang, Neelima Thanneer

{"title":"PmWebSpec: An Application to Create and Manage CDISC-Compliant Pharmacometric Analysis Dataset Specifications","authors":"Lu Chen, Erin Dombrowsky, Baylea Boyle, Chengke Tang, Neelima Thanneer","doi":"10.1208/s12248-024-00910-0","DOIUrl":"https://doi.org/10.1208/s12248-024-00910-0","url":null,"abstract":"<p>A well-documented pharmacometric (PMx) analysis dataset specification ensures consistency in derivations of the variables, naming conventions, traceability to the source data, and reproducibility of the analysis dataset. Lack of standards in creating the dataset specification can lead to poor quality analysis datasets, negatively impacting the quality of the PMx analysis. Standardization of the dataset specification within an individual organization helps address some of these inconsistencies. The recent introduction of the Clinical Data Interchange Standards Consortium (CDISC) Analysis Data Model (ADaM) Population Pharmacokinetic (popPK) Implementation Guide (IG) further promotes industry-wide standards by providing guidelines for the basic data structure of popPK analysis datasets. However, manual implementation of the standards can be labor intensive and error-prone. Hence, there is still a need to automate the implementation of these standards. In this paper, we present PmWebSpec, an easily deployable web-based application to facilitate the creation and management of CDISC-compliant PMx analysis dataset specifications. We describe the application of this tool through examples and highlight its key features including pre-populated dataset specifications, built-in checks to enforce standards, and generation of an electronic Common Technical Document (eCTD)-compliant data definition file. The application increases efficiency, quality and semi-automates PMx analysis dataset, and specification creation and has been well accepted by pharmacometricians and programmers internally. The success of this application suggests its potential for broader usage across the PMx community.</p><h3 data-test=\"abstract-sub-heading\">Graphical Abstract</h3>\u0000","PeriodicalId":501692,"journal":{"name":"The AAPS Journal","volume":"60 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140587836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

LC–MS Characterization and Stability Assessment Elucidate Correlation Between Charge Variant Composition and Degradation of Monoclonal Antibody Therapeutics LC-MS 表征和稳定性评估阐明了电荷变异成分与单克隆抗体治疗药物降解之间的关系

The AAPS Journal Pub Date : 2024-04-03 DOI: 10.1208/s12248-024-00915-9

Himanshu Malani, Anuj Shrivastava, Neh Nupur, Anurag S. Rathore

{"title":"LC–MS Characterization and Stability Assessment Elucidate Correlation Between Charge Variant Composition and Degradation of Monoclonal Antibody Therapeutics","authors":"Himanshu Malani, Anuj Shrivastava, Neh Nupur, Anurag S. Rathore","doi":"10.1208/s12248-024-00915-9","DOIUrl":"https://doi.org/10.1208/s12248-024-00915-9","url":null,"abstract":"<p>Aggregation stability of monoclonal antibody (mAb) therapeutics is influenced by many critical quality attributes (CQA) such as charge and hydrophobic variants in addition to environmental factors. In this study, correlation between charge heterogeneity and stability of mAbs for bevacizumab and trastuzumab has been investigated under a variety of stresses including thermal stress at 40 °C, thermal stress at 55 °C, shaking (mechanical), and low pH. Size- and charge-based heterogeneities were monitored using analytical size exclusion chromatography (SEC) and cation exchange chromatography (CEX), respectively, while dynamic light scattering was used to assess changes in hydrodynamic size. CEX analysis revealed an increase in cumulative acidic content for all variants of both mAbs post-stress treatment attributed to increased deamidation. Higher charge heterogeneity was observed in variants eluting close to the main peak than the ones eluting further away (25-fold and 42-fold increase in acidic content for main and B1 of bevacizumab and 19-fold for main of trastuzumab, respectively, under thermal stress; 50-fold increase in acidic for main and B1 of bevacizumab and 10% rise in basic content of main of trastuzumab under pH stress). Conversely, variants eluting far away from main exhibit greater aggregation as compared to close-eluting ones. Aggregation kinetics of variants followed different order for the different stresses for both mAbs (2nd order for thermal and pH stresses and 0th order for shaking stress). Half-life of terminal charge variants of both mAbs was 2- to 8-fold less than main indicating increased degradation propensity.</p><h3 data-test=\"abstract-sub-heading\">Graphical Abstract</h3>\u0000","PeriodicalId":501692,"journal":{"name":"The AAPS Journal","volume":"50 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140587650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cross-Reactive Polyclonal Antibodies Raised Against GalNAc-Conjugated siRNA Recognize Mostly the GalNAc Moiety 针对 GalNAc 连接的 siRNA 培养的交叉反应多克隆抗体主要识别 GalNAc 分子

The AAPS Journal Pub Date : 2024-04-03 DOI: 10.1208/s12248-024-00914-w

Kimberly K. Ballman, Victoria L. Peek, John H. Sloan, Jingling Li, Robert J. Konrad, Yi Wen

引用次数: 0